Ariad Pharmaceuticals, Inc. (ARIA) Among The Biotech Players To Watch

Page 1 of 2

Three biotech companies are making themselves heard in the stock market. They are making a mark in the life sciences space with their unique mix of science and strategy.

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) is on the focused approach trajectory, using its solid foundation in the sciences to fill the holes left open by big pharma. Celldex Therapeutics, Inc. (NASDAQ:CLDX) is exercising first-mover advantage by developing a novel but potent approach to disease treatment. Array BioPharma Inc (NASDAQ:ARRY) is utilizing the overlaps in research areas to hasten the speed and increase the likelihood of drug discovery while attacking diseases in a more effective manner.

What are these companies doing differently?

On the face of it, Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) doesn’t seem to be following the path of diversification. It has selected a specific market (a very large one at that) – cancer. However, cancer can be of several types, and it has been increasingly plaguing the world for the past few years.

Within the realm of cancer, Ariad has lot of opportunities to diversify. In fact, staying under the cancer umbrella will allow it to benefit from the overlap in research areas among various types of cancers, which could help in developing therapies sooner and for multiple variations of the disease.

The second good thing Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) is doing (commercially) is targeting the needs not met by existing big pharma medications. The idea is to find out the strengths of the best-selling big pharma medications and beat them to take over the market.

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)Following a different path, Celldex Therapeutics, Inc. (NASDAQ:CLDX) has figured out a novel and potent way to attack disease. The body already has a system in place to fight diseases – our immune system. So, why not create a platform of potent antibodies and immunomodulators (immune response modulators) that can be used to develop novel drugs and drug combinations for disease treatment?

They would be the first-in-the-market to utilize such an approach to treat complicated diseases. While Celldex Therapeutics, Inc. (NASDAQ:CLDX) is acquiring smaller companies like CuraGen to add to its collection of antibodies, it is also partnering with companies like Pfizer Inc. (NYSE:PFE) to obtain the financial resources and expertise to develop potential therapy candidates.

Array Biopharma Inc (NASDAQ:ARRY), charting its own course, has channeled its efforts towards cancer and inflammatory disease. These two research areas have a lot of potential for overlap, which can lead to faster development of medications. The company seeks to develop first-in-class drugs, targeting important players in already identified molecular pathways. They also look at increasing the efficacy and safety of existing drugs, or improving upon drugs currently in clinical development by creating superior clinical candidates.

News and financials

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)

Ariad recently presented new preclinical data which shows that its recently approved drug, Iclusig (ponatinib), overcomes drug-resistant mutations found in gastrointestinal stromal tumors. The company currently has four drugs in its pipeline developed in-house, which are being explored for various indications.

The company reported a net loss of $220.9 million for FY 2012, while loss in FY 2011 was $123.6 million. Its operating expenses increased by $103.5 million in 2012 from 2011. This increase was attributed to the development of the company’s product candidates and the preparations involved in the commercial launch of their drug Iclusig.

Celldex Therapeutics, Inc. (NASDAQ:CLDX)

On April 8, Celldex presented positive data showing that their drug candidate, CDX-1127, is effective in activating a patient’s own T cells (type of cell that plays an important role in immune response) against their cancer.

The company incurred a $14.3 million loss in 2012 compared to 2011, mainly due to increased R&D expenditure, especially for late-stage trials. General and administration expenses increased by $0.8 million in 2012 compared to 2011, primarily due to increased personnel-related expenses and rindopepimut-commercialization planning.

Array Biopharma Inc (NASDAQ:ARRY)

Array Biopharma recently reported positive results on two ongoing trials on drug candidates for multiple myeloma. Results of both trials showed that the drug was well tolerated in patients as single agent and in combination therapy. The drug in question, ARRY-520, is a strong multiple myeloma drug with a distinct mechanism of action compared to existing medications.

Revenue has been going up consistently for the past four years, however, the company still operates at a loss. The company has been able to rein in its operating expenses by about 24%.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

7 Most Expensive Cities in the World

5 Least Expensive Cities in the World

10 Celebrities Who Believe In Scientology

10 High Margin Food Products to Build a Business Around

The 10 Most Expensive Clothing Stores in the United States to Get Decked Out At

The 5 Biggest Kickstarter Scams That Swindled Backers’ Donations

The 10 Most Expensive Boarding Schools In the World

50 Crazy Facts About Japan You Won’t Believe

Top 10 Least Expensive Hybrid Cars to Save the Planet With

The 10 Biggest ‘Gate’ Controversies in History

The 10 States with the Highest Nursing Shortages Leaving Their Hospitals Depleted

The 10 Best Value Investment Blogs that Every Investor Must Read

The 6 Cheapest Boarding Schools in Europe 2015

The 5 Most Expensive Cars To Insure in the World

The 10 Most Common Genetically Modified Foods

10 Self-Made Billionaires Who Came From Nothing

The 10 Most Expensive Cities to Live in North America

The 13 Most Expensive Headphones in the World to Represent

The Top 20 Wealthiest Soccer Teams in 2014

4 BuzzWorthy Cannabis Stocks And Some Smoking Derivative Plays

The 10 Healthiest Fast Food Chains in America to Dine At

The 5 Most Expensive Cat Food Brands You Can Spoil Your Kitty With

The 6 Best eCommerce Platforms for Small Businesses

The 10 Worst Mistakes an Entrepreneur Can Make

The 5 Most OP Characters in League of Legends to Carry Games and Crush Foes With

The 5 Best Foods to Eat Before Running that Will Help You Pound the Pavement

10 Glaring Plot Holes in The Walking Dead that a Zombie-Filled Bus Could Drive Through

The 5 Biggest Celebrity Stoners Who Love Their Reefer

The 10 Most Overrated Movies Of All Time by Out-of-Touch Critics

Top 6 Least Expensive Cruise Destinations For 2015 that Will Take You to Paradise

10 States with Lowest Substance Abuse Rates in America

The 14 Most Watched TV Finales Ever

The 10 Best Selling Role Playing Games of All Time for PC

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

Top 6 Cities For The Ultra Rich to Live in Comfort

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

How to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!